The Latest Breaking News from Zoetis

Animal health giant Zoetis beat fourth-quarter sales expectations Tuesday and issued a strong 2023 sales outlook, leading ZTS stock to pop.

Stock picking is an art in a tough market. Learn which companies mutual fund managers believe can grow during economic uncertainty.

How should companies reframe ESG initiatives amid controversy? These executives offer their strategies.

Corporate culture has entered the fourth phase in its history: the integration of purpose and profit, writes Robert Reiss.

Zoetis trimmed its 2022 outlook on Thursday after the animal-health company missed third-quarter forecasts. ZTS stock tumbled.

Fluffy's drugmaker Zoetis offered a mixed second-quarter report Thursday, pushing ZTS stock to sink in early action.

Zoetis (NYSE:ZTS) has outperformed the market over the past 5 years by 13.08% on an annualized basis producing an average annual return of 22.15%. Currently, Zoetis has a market capitalization of $79.88 billion.

The Centre has launched a COVID-19 vaccine for animals such as dogs, lions, leopards, mice and rabbits.

Zoetis (NYSE:ZTS) has outperformed the market over the past 5 years by 11.89% on an annualized basis producing an average annual return of 20.56%. Currently, Zoetis has a market capitalization of $75.58 billion.

Zoetis (NYSE:ZTS) has outperformed the market over the past 5 years by 10.79% on an annualized basis producing an average annual return of 21.83%. Currently, Zoetis has a market capitalization of $79.47 billion.

Rising pet ownership and an increasing focus on healthy livestock have boosted the demand for animal healthcare solutions. Therefore, animal healthcare service providers Zoetis (ZTS) and IDEXX Laboratories (IDXX) should benefit. But the stocks of which of these two companies is a better buy now? Read on to learn our…